Danaher (DHR)
(Delayed Data from NYSE)
$246.58 USD
+0.78 (0.32%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $246.46 -0.12 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
DHR 246.58 +0.78(0.32%)
Will DHR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DHR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DHR
Honeywell (HON) Q1 Earnings Beat, Aerospace Sales Rise Y/Y
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
DHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for DHR
Danaher Corporation: A Good Medium Term Bet
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
Buy Rating on Danaher: Strong Biotech Performance and Growth Potential Despite Market Challenges
Senior Vice President - General Counsel Brian Ellis Sells 4,000 Shares of Danaher Corp (DHR)
Danaher Q1: The Worst Time Has Already Passed